Taxol: The first of the taxanes, an important new class of antitumor agents

Seminars in Oncology

Volumn 19, Issue 6, 1992, Pages 646-662

  Rowinsky, Eric K ^a,b,c   Onetto, Nicole ^a,b,c   Canetta, Renzo M ^a,b,c   Arbuck, Susan G ^a,b,c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c Cancer Therapy Evaluation Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; TAXANE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CARDIOTOXICITY; DOSE RESPONSE; DRUG HALF LIFE; DRUG MECHANISM; DRUG MIXTURE; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; HYPERSENSITIVITY REACTION; INTRAPERITONEAL DRUG ADMINISTRATION; MUCOSA INFLAMMATION; NEUROTOXICITY; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CLINICAL TRIALS; DRUG EVALUATION; DRUG EVALUATION, PRECLINICAL; DRUGS, INVESTIGATIONAL; FEMALE; FORECASTING; HUMAN; LUNG NEOPLASMS; NEOPLASMS; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 0026723301     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Plant antitumor agents VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from taxus brevifolia
2. The chemistry of taxol, a clinically useful anticancer agent
3. Scientists mobilize to increase supply of anticancer drug taxol
4. Promotion of microtubule assembly in vitro by taxol
5. Taxol stabilizes microtubules in mouse fibroblast cells
6. Microtubules
7. Taxol: An antimitotic agent with a new mechanism of action
8. Taxol: A novel investigational antineoplastic agent
9. Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol
10. Tishler RB, Geard R, Hall EJ, et al: Taxol sensitizers human astrocytoma cells to radiation. Cancer Res 52:3495–3497
11. Taxol-requiring mutant of Chinese hamster ovary cells with impaired mitotic spindle activity
12. Cross-resistance of vinblastine- and taxol-resistant mutants of Chinese hamster ovary cells to other anticancer drugs
13. Taxol resistant mutants of Chinese hamster ovary cells: Genetic biochemical, and cross-resistant studies
14. Taxol: Mechanisms of action and resistance
15. 2+ blockers to enhance inhibition by taxol of growth of drug-sensitive and -resistant chinese hamster ovary cells
16. Effects of taxol on cell cycle traverse: Taxol-induced polyploidization as a marker for drug resistance
17. Phase I and pharmacodynamic study of taxol in refractory adult acute leukemia
18. Hypersensitivity reactions from taxol
19. Taxol produces a predominately sensory neuropathy
20. Phase 1 and pharmacologic study of taxol and cisplatin + G-CSF
21. Sequences of taxol and cisplatin: A phase I and pharmacologic study
22. Cardiac disturbances during the administration of taxol
23. Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms
24. Taxol metabolism. Isolation and identification of three major metabolites in rat bile
25. Taxol metabolism in rat and human bile
26. Phase II trial of taxol as second-line therapy for ovarian carcinoma: A gynecologic oncology group study
27. Phase II study of taxol in patients with advanced ovarian cancer
28. Taxol dose intensification in patients with recurrent ovarian cancer
29. Sequencedependent cytotoxicity between cisplatin and the antimicrotubule agents taxol and vincristine
30. Phase II trial of taxol, an active drug in metastatic breast cancer
31. Activity of taxol with recombinant granulocyte colony-stimulating factor as first chemotherapy of patients with metastatic breast cancer
32. Controlled evaluation of Adriamycin (NSC-123127) in patients with disseminated breast cancer
33. Phase I study of taxol and doxorubicin with G-CSF in patients without prior chemotherapy for metastatic breast cancer
34. Phase I study of taxol and doxorubicin (Dox) with G-CSF in previously untreated metastatic breast cancer (MBC)
35. A phase II study of taxol (NSC 125973) in patients (pts) with non-small cell lung cancer (NSCLC)
36. Phase II study of taxol in patients with stage IV nonsmall cell lung cancer (NSCLC): The Eastern Cooperative Oncology Group (ECOG) results
37. Phase II trial or taxol in patients with renal cell carcinoma
38. A phase II study of taxol in patients with malignant melanoma
39. A phase II trial of taxol in metastatic melanoma
40. Taxol (NSC 235973) in advanced hormone refractory prostate cancer: An ECOG phase II trial
41. Pharmacokinetic interactions of cimetidine 1987
42. Reversal of the multidrug resistance phenotype with Cremophor EL, a common vehicle for water-insoluble vitamins and drugs
43. Nerve growth factor prevents toxic neuropathy in mice
44. Nerve growth factor attenuates neurotoxic effects of taxol on spinal cord-ganglion explants from fetal mice
45. A highly efficient approach to natural taxol
46. Application of the vicinal oxyamination reaction with asymmetric induction to the hemisynthesis of taxol and analogues
47. Studies with RP56976 (Taxotere): A semisynthetic analogue of taxol
48. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue
49. A phase I clinical trial of taxotere as a 6 hour infusion repeated every 21 days in patients with refractory solid tumors
50. Phase I trial of taxotere (RP56976)
51. A phase I study of taxotere (RP 56976 NSC 628503) administered as a one hour intravenous infusion on a weekly basis
52. Phase I study of taxotere administered as a 24h h infusion
53. Phase I and pharmacologic study of topotecan (RP56976)
54. Proc Am Assoc Cancer Res